Extramammary paget disease biomarkers and uses thereof
AssigneeThe Catholic University of Korea Industry-Academic Cooperation Foundation
InventorYoung-Bok LEE
Life of this patent
Estimating the term…
Abstract
The present invention relates to extramammary Paget disease biomarkers, such as SPDEF, ARG2, and ABEP1, and uses thereof that were discovered by exploring the molecular profile as well as performing a comprehensive genetic analysis of EMPD. The present invention investigates how EMPD evolves in the context of treatment and may elucidate a potential mechanism of progression to invasion. Furthermore, the biomarkers of the present invention may be usefully used in the diagnosis or treatment of extramammary Paget disease in that the tissue microenvironments and cell types associated with EMPD may be further characterized using spatial transcriptomics.
Claims10
A method of preventing or treating extramammary Paget disease, comprising the following steps:
- measuring the level of one or more selected from the group consisting of an SAM pointed domain containing ETS transcription factor (SPDEF), arginase 2 (ARG2), and adipocyte enhancer-binding protein 1 (ABEP1) from a biological sample isolated from a subject;
- comparing the measured level of one or more selected from the group consisting of SPDEF, ARG2, and ABEP1 with the level in a biological sample isolated from the control;
- when the level of any one or more selected from the group consisting of SPDEF, ARG2, and ABEP1 in the biological sample isolated from the subject is higher than the level in the biological sample isolated from the control, determining this case to be extramammary Paget disease;
- and
- administering an agent for preventing or treating extramammary Paget disease to a subject determined to have extramammary Paget disease.
A method of screening for an agent for preventing or treating extramammary Paget disease, comprising the following steps:
- measuring the level of any one or more selected from the group consisting of an SAM pointed domain containing ETS transcription factor (SPDEF), arginase 2 (ARG2), and adipocyte enhancer-binding protein 1 (ABEP1) from a biological sample isolated from an animal model of extramammary Paget disease administered a candidate material;
- and
- when the level of any one or more selected from the group consisting of SPDEF, ARG2, and AEBP1 in the biological sample isolated from the animal model decreases, selecting the candidate material as an agent for preventing or treating extramammary Paget disease.
A kit for screening for an agent for preventing or treating extramammary Paget disease, comprising:
- i) a composition comprising, as an active ingredient, an agent for measuring the level of one or more selected from the group consisting of an SAM pointed domain containing ETS transcription factor (SPDEF), arginase 2 (ARG2), and adipocyte enhancer-binding protein 1 (ABEP1);
- and
- ii) instructions.
Dependencies are inferred from the claim text.